CHILDRENS CANCER GROUP--COMPETITIVE GRANT RENEWAL

玛嘉烈公主儿童医院（Princess Margaret Hospital for Children，PMH）是西澳大利亚州唯一的高等教育附属儿科教学医院，并在该州提供唯一的多学科儿科肿瘤服务，该州人口为200万。 PMH是北美以外唯一一家被接受为CCG成员（1990年11月当选）的医院。 1992年11月从试用成员晋升为正式成员。 在过去的12个月里，PMH已经进入了70名患者的CCG治疗，生物和非治疗研究。 至于1997年根据标准化的CCG排名系统进行的总体机构排名，玛氏医院排名第19位（1996年为26位），是CCG所有附属医院中进步最快的。 肿瘤科设在一个专门建造的“全面护理单位”，其中包括在一个地方管理癌症儿童及其家人所需的所有服务和学科，包括住院、造血干细胞移植、当天护理、门诊、治疗室、药房、数据管理、社会工作、教室和护士联络设施。肿瘤科的目标有四个方面：（1）提供最先进的多学科管理，最大限度地提高儿童肿瘤疾病的治愈概率。 (2)量身定制治疗方案，以最大限度地减少急性毒性和长期有害后遗症。 (3)通过申请IRB批准的合作组临床试验，支持科学合理的临床研究. (4)通过积极支持CCG批准的生物学研究促进转化研究。这些目标的最佳实现是通过PMH的承诺，以履行所有必要的要求和责任，保持与儿童癌症小组的正式成员。PMH肿瘤科的长期目标是在CCG活动中发挥更积极的作用，包括指导和研究委员会以及战略小组成员。

Princess Margaret Hospital for Children (PMH) is the sole tertiary university affiliated paediatric teaching hospital for the State of Western Australia and provides the only multidisciplinary paediatric oncology service in the state, which has a population of 2 million. PMH is the only hospital outside North America honoured by being accepted as a CCG member (elected November 1990). Promotion from probationary to full membership was achieved in November 1992. In the last 12 months PMH has entered 70 patients on CCG therapeutic, biologic and non- therapeutic studies. With respect to the overall institutional ranking for 1997 based on a standardised CCG ranking system, PMH achieved a ranking of 19 (compared with 26 in 1996), the best incremental improvement of all CCG affiliated hospitals. The Oncology Division is housed in a purpose built "Total Care Unit" containing all services and disciplines in the one locality needed to manage children with cancer their families and includes inpatient, haemopoietic stem cell transplant, same day care, outpatient, treatment rooms, pharmacy, data management, social work, school room and nurse liaison facilities. The Oncology Division goals are four-fold: (1) Provide state of the art multidisciplinary management which will maximise probabilities of cure for oncological diseases in children. (2) Tailor curative therapy to minimise both acute toxicity and long term deleterious sequelae. (3) Support scientifically sound clinical research through the application of IRB approved co- operative group clinical trials. (4) Promote translational research through active support of CCG approved biologic studies. These aims are best achieved by PMH's commitment to fulfilling all the requirements and responsibilities necessary in maintaining full membership with the Children's Cancer Group. The long term objective of the Oncology Division at PMH is to play a more pro-active role in CCG activities including steering and study committees and strategy group membership.